As of 3:59pm ET
| +0.39 / +3.78%|
The 4 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 14.00, with a high estimate of 15.75 and a low estimate of 13.00. The median estimate represents a +30.84% increase from the last price of 10.70.
The current consensus among 4 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.